| Jonathan M. N. Rigby |
Jonathan M. N. Rigby was the founder of Zogenix, Inc. (2006) as Vice President-Business Development. Current jobs include Chairman & Chief Executive Officer at Sernova Biotherapeutics, Inc. (2025), Chairman at Association of Needle-Free Injection Manufacturers (2010), Chairman & Chief Business Officer at BioPlus Acquisition Corp. (2021), Director at Thermalin, Inc., Director at ImmunoMolecular Therapeutics, Inc. (2021), and Director at Oncolytics Biotech, Inc. (2022). Former jobs include President, Chief Executive Officer & Director at SteadyMed Ltd. (2011-2020), President, Group CEO & Director at Revolo Biotherapeutics Ltd. (2020-2024), President, Chief Executive Officer & Director at SteadyMed Therapeutics, Inc. (2011-2019), Chairman at CollPlant Biotechnologies Ltd. (2019), Independent Non-Executive Director at Xeris Pharmaceuticals, Inc. (2016-2019), Principal at Merck & Co., Inc., Vice President-Business Development at Aradigm Corp. (2002-2006), and Head-Business Development & Sales at Respironics Ltd. (1995-2002). Education includes an undergraduate degree from The University of Sheffield and an MBA from the University of Portsmouth. |
| Ross Haghighat |
Ross Haghighat is the founder of CoreTek, Inc. (1994), Aduro BioTech, Inc. (2008), Triton Systems, Inc. (1992), and FRX Polymers, Inc. (2007). Current jobs include Co-Chief Executive Officer & Director at Epiphany Technology Acquisition Corp. (2022), Chairman at FRX Innovations, Inc., Non-Executive Director at Emefcy Ltd. (2015), Director at Avertix Medical Systems, Inc. (2024), Director at SI2 Technologies, Inc. (2009), Director at ACT Ltd., Director at Electriq Global Ltd. (2018), Director, Chief Executive & Financial Officer at Enterprise 4.0 Technology Acquisition Corp. (2023), Managing Partner at Newburyport Partners Pty Ltd., Chief Executive & Financial Officer at BioPlus Acquisition Corp., and Partner at Jasper Capital Partners. Former jobs include Chairman at Sernova Biotherapeutics, Inc. (2025), Chairman at Vitasora Health Ltd. (2010-2014), Director at Sensera, Inc., Director at Mavatar Technologies, Inc., Independent Non-Executive Director at Emefcy Group Ltd., Director at Redrock Biometrics, Inc., Independent Director at CITIC Capital Acquisition Corp., Independent Director at Chinook Therapeutics, Inc. (2009-2023), Non-Executive Director at Fluence Corp. Ltd. (2015-2024), and Senior Engineer at Foster-Miller, Inc. Education includes an MBA from Boston College and undergraduate and graduate degrees from Rutgers State University of New Jersey (1985, 1986). |
| Shawn Mikael Cross |
Shawn Mikael Cross currently works at Flexion Therapeutics, Inc., as Chief Financial Officer & Director, BioPlus Acquisition Corp., as Independent Director from 2021, and Pacira Biosciences, Inc., as Chief Financial Officer from 2024. Mr. Cross also formerly worked at GT Biopharma, Inc., as Chairman & Chief Executive Officer in 2018, Applied Molecular Transport, Inc., as Chairman & Chief Executive Officer in 2023, Citizens JMP Securities LLC, as Managing Director from 2018 to 2020, Wells Fargo Securities LLC, as Managing Director from 2010 to 2015, Cyclo Therapeutics, Inc., as Independent Director from 2023 to 2025, Deutsche Bank Securities, Inc., as Principal, Deutsche Bank AG, as Principal, Thomas Weisel Partners LLC, as Principal, Alex. Brown & Sons, Inc., as Principal, and the University of Washington Medical Center, as Principal. Mr. Cross received his undergraduate degree from the University of California, Los Angeles and Masters Business Admin degree from Columbia Business School. |
| Louis G. Lange |
Louis G. Lange founded CV Therapeutics, Inc. in 1990, where he worked as Chairman, CEO & Chief Scientific Officer from 1992 to 2009, Cardiogen Sciences, Inc. in 2014, where he worked as Director from 2014 to 2015, Rapidscan Pharma Solutions, Inc. in 2010, where he worked as Chairman, and various other companies. Dr. Lange also currently works at InCarda Therapeutics, Inc., as Director, Maverix Biomics, Inc., as Director from 2014, NewAmsterdam Pharma BV, as Non-Executive Director, and various other companies. Dr. Lange also formerly worked at CymaBay Therapeutics, Inc., as Chairman from 2009 to 2015, CardioDx, Inc., as Chairman, Institute for Systems Biology, as Chairman, and various other companies. Dr. Lange received his undergraduate degree from Rochester Christian University and doctorate degree from Harvard Medical School. |
| Glen Giovannetti |
Glen Giovannetti is currently serving as a Director at XWPharma Ltd., Revolo Biotherapeutics Ltd., Teon Therapeutics, Inc., and Life Science Cares, Inc. He is also an Independent Director at Enterprise 4.0 Technology Acquisition Corp. He previously worked as a Director at Biotechnology Innovation Organization from 2011 to 2014 and as a Partner at Ernst & Young LLP from 1984 to 2020. He completed his undergraduate degree from Linfield College. |
